Connect with us

Medical Devices

Camber Spine Launches National Rollout of Complete Device System to Support OLIF Technique

Avatar

Published

on

KING OF PRUSSIA, Pa.–(BUSINESS WIRE)– Camber Spine, a leading innovator in spine and medical technologies, has announced the national rollout of a complete set of devices and tools required to perform the Oblique Lateral Interbody Fusion Surgery (OLIF) technique. Camber’s OLIF technology platform, a continuation of the company’s ongoing portfolio of product development of surgical solutions for anterior column reconstruction, enables surgeons to take advantage of the natural corridor and access the anterior spine (L2-S1) through an oblique surgical approach, anterior to the psoas muscle, which is performed while the patient is in a lateral position.

The SPIRA®-O Open Matrix OLIF System incorporates the company’s proprietary open architecture and surface technology, and is the only comprehensive system on the market designed specifically for the OLIF spinal surgery approach. Its inserter location, for example, is placed at the optimal angle for atraumatic insertion. And no toggling of instruments in situ is required because Camber’s instruments are designed for safe implant delivery under direct visualization. Another highlight of the technology platform is its design for optimal cage placement, helping surgeons avoid contralateral nerve impingement.

The OLIF technique is a methodology designed by surgeons seeking a less complicated, simpler approach to treating complex spinal pathologies. The procedure gives surgeons the ability to access multiple levels through one incision without having to reposition the patient and offers excellent disc space visualization.

Camber also announced a multi-city, hands-on cadaveric OLIF training series that kicked off last month. Additional sessions are confirmed for May 1st in Las Vegas; September 18th in Austin; and November 6th in Miami. For questions, more information or to register for training, surgeons can contact Brooks McAdam at bmcadam@cambermedtech.com.

“The national rollout of our complete device system to support the OLIF technique is a significant milestone for Camber Spine,” said Daniel A. Pontecorvo, Camber’s CEO. “Our interactions with surgeons at the training sessions to date have been highly positive. Our patented and award-winning OLIF technology platform, which empowers surgeons to have smooth implant delivery through the most natural corridor to the disc space, has the potential to change the way spine care is delivered. We are incredibly excited to help make this technique available to surgeons around the country and beyond.”

Innovative spine and medical technology company Camber Spine Technologies is dedicated to creating surgeon-designed solutions in MIS and minimally disruptive access for the treatment of complex spinal pathology. Incorporating state-of-the-art manufacturing, 3-D printing, and an acute sensitivity to patient anatomy, Camber Spine is making quantum leaps in the spinal fusion market. Learn more at CamberMedtech.com.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/camber-spine-launches-national-rollout-of-complete-device-system-to-support-olif-technique/?s=93

Medical Devices

BD’s Commitment to Address Climate Change

Avatar

Published

on

As part of its 2030+ sustainability goals, BD pledges carbon neutrality by 2040 across direct operations

FRANKLIN LAKES, N.J., April 22, 2021 /PRNewswire/ — In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming the first phase of its 2030+ sustainability goals – climate change targets.

“At BD, environmental, social and corporate governance (ESG) issues are a strategic imperative and essential to the long-term resilience of our business,” said Tom Polen, CEO and president, BD. “We know that climate change is a critical issue and we are doing our part in helping to address it. As a leading medical technology company, we are focused on the interconnections between climate and health, which is why we believe in setting science-based targets to help prevent the worst effects of climate change. BD’s pledge to be carbon neutral by 2040 across direct operations is consistent with our long-standing global health leadership.

BD recognizes the significant impact climate change could have on our operations, our supply chain and, most urgently, on human health. The Intergovernmental Panel on Climate Change has warned that global warming must not exceed 1.5°C to avoid the catastrophic impacts of climate change. Therefore, setting ambitious emission reduction targets based on science is an important part of our overall strategy to manage and mitigate the impacts of climate change.”

BD’s climate change targets are aimed at reducing its contribution to global greenhouse gas (GHG) emissions from direct operations. BD is committing to reduce Scope 1 and 2 GHG emissions 46% by 2030 (from its 2019 baseline) and to be carbon neutral across its direct operations by 2040. This science-based target is aligned with the 1.5°C global emissions reduction pathway. In addition, BD continues to work with supply chain partners to quantify and reduce Scope 3 GHG emissions.

These new climate targets build upon BD’s long-standing commitment to environmental stewardship. To date, the company has achieved a 48% reduction in Scope 1 and 2 GHG emissions (on an absolute basis) from its baseline year of 2008, as part of its previous set of sustainability goals. Earlier this year, BD became one of more than 1,000 organizations that support the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).

For more information about BD’s sustainability programs and to review the 2019 Sustainability report and 2019 Climate Change Management report, visit https://www.bd.com/en-us/company/sustainability-at-bd.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many of these risks and uncertainties are beyond the company’s control, including without limitation, challenges relating to economic, competitive, governmental, and technological factors affecting our operations, markets, and products, and other factors listed in our 2020 Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bds-commitment-to-address-climate-change-301274599.html

SOURCE BD (Becton, Dickinson and Company)

Company Codes: NYSE:BDX

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/bd-s-commitment-to-address-climate-change/?s=93

Continue Reading

Medical Devices

Titan Medical Expands Senior Leadership Team

Avatar

Published

on

Kristen Galfetti Appointed as Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President, Finance

TORONTO–(BUSINESS WIRE)– TITAN Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Kristen Galfetti, MBA, as its Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President Finance. Ms. Galfetti will be located in Boston and Mr. Huang will be located in Toronto.

“It is a pleasure to welcome both Kristen and Chien to Titan Medical. As the Titan team continues to grow and advance our Enos™ robotic single access surgery system toward human clinical studies, we look forward to these two accomplished leaders significantly contributing to our success,” said David McNally, President and Chief Executive Officer of Titan. “Kristen and Chien have each demonstrated a record of success in their respective fields, and we are proud that they have joined our leadership team.”

Ms. Galfetti has over 20 years of experience leading investor relations and corporate communications programs. Most recently, Ms. Galfetti provided consulting services to small and medium companies in the life science industries. Her corporate experience includes serving as Vice President, Investor Relations & Corporate Communications at Cynapsus Therapeutics. Prior to Cynapsus, she was Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director, Corporate Communications and Investor Relations at AMAG Pharmaceuticals. Prior to AMAG, Ms. Galfetti held Investor Relations roles of increasing responsibility at Genzyme Corporation. Ms. Galfetti holds a Bachelor of Arts in Political Science from the University of Vermont and a Master of Business Administration (with distinction) from Bentley University.

Mr. Huang is a financial executive with over 20 years of experience developing and implementing financial models and systems, and accounting practices to support the achievement of strategic corporate objectives. Mr. Huang has strong expertise in evaluating investment opportunities and long-term value creation as well as extensive knowledge of IFRS and U.S. GAAP reporting requirements. Most recently, he served as Senior Vice President, Corporate Finance at Quarterhill Inc., where he led the finance systems migration and reorganized key business processes, streamlining external reporting processes. Prior to Quarterhill, Mr. Huang served as Vice President, Finance at Aralez Pharmaceuticals, responsible for implementing systems upgrades, negotiating potential divestitures and advising on private equity financing. Prior to this, Mr. Huang was Senior Director, Finance at Astellas Pharma. Mr. Huang holds a Bachelor of Science in Physiology from the University of Toronto, a Graduate Diploma in Public Accountancy from McGill University, and has Chartered Accountant Designation.

About Titan Medical

Titan Medical Inc., a medical device company headquartered in Toronto, is focused on developing robotic assisted technologies for application in single access surgery. The Enos system, by Titan Medical, is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments, and an ergonomic surgeon workstation. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.

Certain of Titan’s robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system.

Enos™ is a trademark of Titan Medical Inc.

For more information, please visit www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of the Company’s future growth, results of operations, performance, and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements, including, without limitation, references to: the Company’s focus on the design and development of surgical technologies for robotic single access surgery, the Enos system is being developed with dual 3D and 2D high-definition vision systems, multi-articulating instruments and an ergonomic surgeon workstation, and that Titan intends to initially pursue gynecologic surgical indications. These statements reflect management’s current beliefs, and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form and Form 40-F for the fiscal year ended December 31, 2020 (which may be viewed at www.sedar.com and at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, the Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/titan-medical-expands-senior-leadership-team/?s=93

Continue Reading

Medical Devices

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

Avatar

Published

on

Proximie is a health technology platform company focused on digitizing operating and diagnostic rooms.

Today the company announced the completion of its $38 million Series B equity financing. The round was led by F-Prime Capital, with participation from new investors Questa Capital, Eight Roads, Maverick Ventures, and the support of existing investors Global Ventures, BECO Capital, and Cedar Mundi Ventures.

The company’s mission is to save lives by sharing the world’s best clinical practices. The platform combines human expertise with the power of augmented reality (AR), machine learning (ML), artificial intelligence (AI), and advanced telecommunications.

Proximie will use the proceeds to accelerate its expansion in the U.S. and European markets. Significant investment will be directed toward commercial efforts, including new technology implementations, in addition to research and development.

The company was founded by Dr. Nadine Hachach-Haram FRCS (Plastics) – (B.E.M., British Empire Medal), in 2016. The company is building a network of operating rooms, where every interaction is captured, digitized, cataloged, and analyzed. By digitizing surgery, Proximie can accelerate the adoption of best practices and help to create better patient outcomes.

Proximie has enjoyed rapid growth over the last 12 months, having conducted over 10,000 surgical interactions in 300 hospitals in over 40 countries.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/proximie-raises-38m-series-b/

Continue Reading

Medical Devices

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

Avatar

Published

on

Proximie is a health technology platform company focused on digitizing operating and diagnostic rooms.

Today the company announced the completion of its $38 million Series B equity financing. The round was led by F-Prime Capital, with participation from new investors Questa Capital, Eight Roads, Maverick Ventures, and the support of existing investors Global Ventures, BECO Capital, and Cedar Mundi Ventures.

The company’s mission is to save lives by sharing the world’s best clinical practices. The platform combines human expertise with the power of augmented reality (AR), machine learning (ML), artificial intelligence (AI), and advanced telecommunications.

Proximie will use the proceeds to accelerate its expansion in the U.S. and European markets. Significant investment will be directed toward commercial efforts, including new technology implementations, in addition to research and development.

The company was founded by Dr. Nadine Hachach-Haram FRCS (Plastics) – (B.E.M., British Empire Medal), in 2016. The company is building a network of operating rooms, where every interaction is captured, digitized, cataloged, and analyzed. By digitizing surgery, Proximie can accelerate the adoption of best practices and help to create better patient outcomes.

Proximie has enjoyed rapid growth over the last 12 months, having conducted over 10,000 surgical interactions in 300 hospitals in over 40 countries.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/proximie-raises-38m-series-b/

Continue Reading
Blockchain3 days ago

Mining Bitcoin: How to Mine Bitcoin

Fintech4 days ago

Fintech offers brokers better commissions after BID

Esports5 days ago

OWL 2021 Power Rankings – #9 Guangzhou Charge

Coinbase hourly chart
Blockchain3 days ago

Coinbase Addresses Future Revenue Concerns With Plans to Become Crypto’s Amazon

PR Newswire4 days ago

Hello Pal Signs Definitive Purchase Agreement to Acquire Interest in Dogecoin/Litecoin Mining Assets

Esports5 days ago

CDL Challengers Elite Stage 3 Preview

Esports5 days ago

xQc Banned From NoPixel GTA RP Server Once Again

Esports4 days ago

Twitch streamer Lando Norris takes Italian F1 Grand Prix podium

Esports4 days ago

Three takeaways from the SWT Japan Ultimate Online Qualifier

Esports4 days ago

Cloud9 Perkz says Kassadin can’t ever be balanced in LoL

Blockchain3 days ago

Did Coinbase Insiders Really Cash Out? It’s Complicated

Blockchain5 days ago

Ontario Securities Commission Just Approved New ETH ETFs

Nano Technology4 days ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Esports5 days ago

Valorant: Meet the top 4 EU teams qualified for VCT EMEA Stage 2 Challengers Final

Fintech4 days ago

HashChing acquires Mystro to further expand its offering to mortgage brokers

Esports5 days ago

Nigma make impressive debut versus Team Secret in Europe Season 2 DPC league

Aviation3 days ago

United Airlines a first quarter 2021 net loss of $1.4 billion

Blockchain3 days ago

Gary Gensler is now head of the SEC. What comes next?

Blockchain4 days ago

Krypto Person der Woche Alex Mashinsky

Blockchain4 days ago

Binance Team to Burn all the Allocated BNB Token

Trending